New injection for rheumatoid arthritis enters first human safety tests
NCT ID NCT05576012
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new biologic drug called SOL-116 in 56 healthy volunteers and people with rheumatoid arthritis. The main goal was to check safety and how the body processes the drug, not whether it works. Participants received a single injection of SOL-116 or a placebo, and researchers monitored for side effects. This is the first step in seeing if SOL-116 could become a future treatment for rheumatoid arthritis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SOL-116 (a biologic drug given as an injection)
What this could lead to
If safe and effective in later trials, SOL-116 could become a new treatment option to help control rheumatoid arthritis symptoms.
What could go wrong
This is a very early Phase 1 study focused on safety, not on whether the drug works. It involves only 56 people, so results may not apply to everyone, and the drug may fail in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHDR (Stichting Centre for Human Drug Research)
Leiden, Netherlands
-
QPS Netherlands B.V.
Groningen, Netherlands